AEZS-132, a new orally bioavailable PI3K/Erk inhibitor with antitumor effects

被引：0

作者：

Seipelt, I. ^{[1
]}

Gerlach, M. ^{[2
]}

Baasner, S. ^{[1
]}

Blumenstein, L. ^{[1
]}

Mueller, G. ^{[2
]}

Aicher, B. ^{[1
]}

Engel, J. ^{[3
]}

Guenther, E. ^{[4
]}

Teifel, M. ^{[1
]}

机构：

[1] Aeterna Zentaris GmbH, Preclin Dev, Frankfurt, Germany

[2] Aeterna Zentaris GmbH, Med Chem, Frankfurt, Germany

[3] Aeterna Zentaris GmbH, Management Board, Frankfurt, Germany

[4] Aeterna Zentaris GmbH, Alliance Management, Frankfurt, Germany

来源：

EJC SUPPLEMENTS | 2010年 / 8卷 / 07期

关键词：

D O I：

10.1016/S1359-6349(10)71902-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：66 / 66

页数：1

共 50 条

[1] AEZS-126, a new orally bioavailable PI3K inhibitor in preclinical development
Seipelt, Irene
Baasner, Silke
Gerlach, Matthias
Teifel, Michael
Fensterle, Joachim
Blumenstein, Lars
Mueller, Gilbert
Guenther, Eckhart
CANCER RESEARCH, 2009, 69
[2] AEZS-129, an orally active PI3K inhibitor in preclinical development
Seipelt, I.
Guenther, E.
Baasner, S.
Blumenstein, L.
Mueller, G.
Fensterle, J.
Engel, J.
Teifel, M.
Gerlach, M.
EJC SUPPLEMENTS, 2010, 8 (07): : 38 - 38
[3] Dual PI3K/ERK inhibitor AEZS-136, a potent antitumor compound under preclinical development
Gerlach, Matthias
Seipelt, Irene
Blumenstein, Lars
Jung, Kai
Schuster, Tilmann
Mueller, Gilbert
Guenther, Eckhard
Engel, Juergen
Teifel, Michael
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
[4] Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor
Martinez Gonzalez, Sonia
Isabel Hernandez, Ana
Varela, Carmen
Rodriguez-Aristegui, Sonsoles
Lorenzo, Milagros
Rodriguez, Antonio
Rivero, Virginia
Ignacio Martin, Jose
Gustav Saluste, Carl
Ramos-Lima, Francisco
Cendon, Elena
Cebrian, David
Aguirre, Enara
Gomez-Casero, Elena
Albarran, Maribel
Alfonso, Patricia
Garcia-Serelde, Beatriz
Oyarzabal, Julen
Rabal, Obdulia
Mulero, Francisca
Gonzalez-Granda, Teresa
Link, Wolfgang
Fominaya, Jesus
Barbacid, Mariano
Bischoff, James R.
Pizcueta, Pilar
Pastor, Joaquin
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (10) : 3460 - 3466
[5] Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor
Shapiro, Geoffrey I.
Edelman, Gerald
Calvo, Emiliano
Aggarwal, Sanjay K.
Laird, A. Douglas
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3594S - 3594S
[6] Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR
Martinez Gonzalez, Sonia
Isabel Hernandez, Ana
Varela, Carmen
Lorenzo, Milagros
Ramos-Lima, Francisco
Cendon, Elena
Cebrian, David
Aguirre, Enara
Gomez-Casero, Elena
Albarran, M. I.
Alfonso, Patricia
Garcia-Serelde, Beatriz
Mateos, Genoveva
Oyarzabal, Julen
Rabal, Obdulia
Mulero, Francisca
Gonzalez-Granda, Teresa
Link, Wolfgang
Fominaya, Jesus
Barbacid, Mariano
Bischoff, James R.
Pizcueta, Pilar
Blanco-Aparicio, Carmen
Pastor, Joaquin
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (16) : 5208 - 5214
[7] Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines
Shen, Sida
He, Xiangyu
Yang, Zheng
Zhang, Liang
Liu, Yingtao
Zhang, Zhiyuan
Wang, Weiwei
Liu, Wei
Li, Yufeng
Huang, Dong
Sun, Kai
Ni, Xiaojing
Yang, Xu
Chu, Xinxin
Cui, Yumin
Lv, Qiang
Lan, Jiong
Zhou, Fusheng
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (07): : 719 - 724
[8] In vitro profiling of the potent and selective PI3K inhibitor AEZS-126
Seipelt, Irene
Gerlach, Matthias
Blumenstein, Lars
Mueller, Gilbert
Teifel, Michael
Polymeropoulos, Emmanuel
Guenther, Eckhard
CANCER RESEARCH, 2009, 69
[9] ANTITUMOR ACTIVITY OF PI3K ANTAGONIST AEZS126*IN MODELS OF TRIPLE NEGATIVE BREAST CANCER
Engel, J. B.
Schmidt, H.
Haeussler, S.
Diessner, J.
Hahne, J.
Meyer, S.
Wischhusen, J.
Dietl, J.
Hoenig, A.
ANTICANCER RESEARCH, 2011, 31 (05) : 1967 - 1968
[10] Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147
Foster, Paul G.
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3592S - 3592S

← 1 2 3 4 5 →